Levamisole in cancer treatment: modifications in time of cellular immunity. (Preliminary report).
Some preliminary observations are reported on a restricted case-list of patients with neoplastic disease in remission, after suitable treatment (surgical and/or radiant and/or antiblastic), treated with levamisole. The results obtained, even if preliminary, stress the close relationship between the immunorestorative effect and the length of the administration. Besides, the restoration of the secondary delayed immunity turned out promptly, in comparison with the primary delayed immunity. Very scanty the side effects observed.
D000328:Adult; D000368:Aged; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006394:Hemangiosarcoma / Q000188:drug therapy; D006801:Humans; D007111:Immunity, Cellular; D007978:Levamisole / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D007978:Levamisole